Natera (NASDAQ:NTRA) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of Natera (NASDAQ:NTRA) from a hold rating to a sell rating in a research note published on Monday morning.

Several other research firms have also issued reports on NTRA. Piper Sandler increased their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Guggenheim boosted their price objective on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. JPMorgan Chase & Co. increased their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Robert W. Baird boosted their price target on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday. Finally, The Goldman Sachs Group increased their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $172.69.

Natera Trading Down 8.0 %

NASDAQ NTRA opened at $143.11 on Monday. The company has a fifty day moving average of $167.44 and a 200 day moving average of $147.35. The company has a market capitalization of $18.89 billion, a PE ratio of -81.31 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera has a 1 year low of $83.13 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Research analysts forecast that Natera will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In related news, insider John Fesko sold 663 shares of the stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares of the company’s stock, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 4,858 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $166.59, for a total value of $809,294.22. Following the completion of the sale, the insider now directly owns 114,912 shares in the company, valued at approximately $19,143,190.08. The trade was a 4.06 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 208,299 shares of company stock worth $34,948,265. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Chartwell Investment Partners LLC boosted its holdings in Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after acquiring an additional 11,362 shares during the period. Cerity Partners LLC boosted its stake in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Natera in the third quarter valued at approximately $385,000. Everence Capital Management Inc. purchased a new stake in Natera during the 4th quarter worth approximately $573,000. Finally, First Turn Management LLC acquired a new stake in Natera during the 3rd quarter worth approximately $19,760,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.